Keros Therapeutics (NASDAQ:KROS) Issues Quarterly Earnings Results

Keros Therapeutics (NASDAQ:KROS) posted its quarterly earnings results on Thursday. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.29), FiscalAI reports. The business had revenue of $0.37 million during the quarter, compared to analyst estimates of $1.93 million. Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.

Keros Therapeutics Price Performance

KROS traded down $0.95 on Thursday, reaching $11.04. 646,852 shares of the company traded hands, compared to its average volume of 389,516. The company has a market cap of $218.50 million, a price-to-earnings ratio of 6.07 and a beta of 0.95. The stock’s 50 day moving average price is $11.55 and its 200-day moving average price is $15.77. Keros Therapeutics has a 52-week low of $10.32 and a 52-week high of $22.55.

Wall Street Analyst Weigh In

Several research analysts have issued reports on KROS shares. Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Wall Street Zen downgraded shares of Keros Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Keros Therapeutics presently has an average rating of “Hold” and an average target price of $20.40.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KROS. Tower Research Capital LLC TRC raised its holdings in shares of Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares in the last quarter. New York State Common Retirement Fund grew its stake in Keros Therapeutics by 264.1% in the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after purchasing an additional 7,700 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Keros Therapeutics by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after purchasing an additional 988 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new position in Keros Therapeutics in the 3rd quarter worth about $176,000. Finally, XTX Topco Ltd purchased a new stake in shares of Keros Therapeutics during the 4th quarter worth about $212,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.